Success Metrics

Clinical Success Rate
71.4%

Based on 10 completed trials

Completion Rate
71%(10/14)
Active Trials
0(0%)
Results Posted
80%(8 trials)
Terminated
4(24%)

Phase Distribution

Ph not_applicable
1
6%
Ph phase_2
8
47%
Ph phase_3
1
6%
Ph phase_4
3
18%
Ph early_phase_1
1
6%
Ph phase_1
2
12%

Phase Distribution

3

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 1Safety & dosage
2(12.5%)
Phase 2Efficacy & side effects
8(50.0%)
Phase 3Large-scale testing
1(6.3%)
Phase 4Post-market surveillance
3(18.8%)
N/ANon-phased studies
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(10)
Terminated(4)
Other(3)

Detailed Status

Completed10
Terminated4
unknown3

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.3%)
Phase 12 (12.5%)
Phase 28 (50.0%)
Phase 31 (6.3%)
Phase 43 (18.8%)
N/A1 (6.3%)

Trials by Status

unknown318%
completed1059%
terminated424%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT06091020Phase 2

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury

Completed
NCT06604832Phase 1

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Completed
NCT02088632Phase 2

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

Terminated
NCT05585398Phase 1

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

Completed
NCT05222607

Longitudinal Evaluation and Real-world Evidence of NT201

Terminated
NCT05305768Early Phase 1

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

Unknown
NCT02207946Phase 2

Botulinum Toxin A to Treat Arm Tremor

Completed
NCT01614743Phase 2

A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea

Completed
NCT04290169Not Applicable

Effect of Video Game-assisted and BoNT-A Injection Therapy on Spasticity, Activity and Participation in CP Patients

Unknown
NCT03044080Phase 4

Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot

Completed
NCT02096081Phase 4

The Treatment of Glabellar Frown Lines

Completed
NCT01603459Phase 3

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

Completed
NCT01931878Phase 2

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Completed
NCT02419313Phase 2

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Completed
NCT01931865Phase 2

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

Terminated
NCT01583478Phase 4

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

Unknown
NCT01515371Phase 2

Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring

Terminated

All 17 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
17